Top

Published in:

01-03-2014 | Review Article

Biomarkers for predicting the response of esophageal squamous cell carcinoma to neoadjuvant chemoradiation therapy

Authors: Hiroshi Okumura, Yasuto Uchikado, Tetsuro Setoyama, Masataka Matsumoto, Tetsuhiro Owaki, Sumiya Ishigami, Shoji Natsugoe

Published in: Surgery Today | Issue 3/2014

Abstract

This review summarizes and evaluates the literature regarding the biomarkers for predicting the response and/or prognosis of esophageal squamous cell carcinoma (ESCC) patients treated with neoadjuvant chemoradiation therapy (CRT). There are seven categories of molecules known to correlate with the response and/or prognosis: tumor suppressors (p53, p21), cell cycle regulators (Cyclin D1, CDC25B, 14-3-3sigma), DNA repair molecules (p53R2, ERCC1), drug resistance proteins [metallothionein (MT)], angiogenic factors (VEGF), molecules involved in cell proliferation/invasion/metastasis (Ki-67, COX-2) and hedgehog signaling molecules (Gli-1). Of the above molecules, the tumor suppressor p53 is expected to be a representative biomarker for predicting the response and prognosis. The cell cycle markers CDC25B and 14-3-3sigma have potential as response biomarkers independent of the p53 status. The DNA repair markers, p53R2 or ERCC1, angiogenic molecule (VEGF), and hedgehog signaling pathway factor Gli-1 also have potential to predict the response and prognosis of ESCC. However, there are still many unanswered questions with regard to predicting the clinical effects of neoadjuvant CRT.

Natsugoe S, Okumura H, Matsumoto M, et al. Randomized controlled study on preoperative chemoradiotherapy followed by surgery versus surgery alone for esophageal squamous cell cancer in a single institution. Dis Esophagus. 2006;19:468–72.PubMedCrossRef

John MJ, Flam MS, Mowry PA, et al. Radiotherapy alone and chemoradiation for nonmetastatic esophageal carcinoma. A critical review of chemoradiation. Cancer. 1989;632:397–403.

Naunheim KS, Petruska P, Roy TS, et al. Preoperative chemotherapy and radiotherapy for esophageal carcinoma. J Thorac Cardiovasc Surg. 1992;103:887–93.PubMed

Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science. 1994;266:807–10.PubMedCrossRef

Caelles C, Helmberg A, Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature. 1994;370:220–3.PubMedCrossRef

Wagata T, Shibagaki I, Imamura M, Shimada Y, Toguchida J, Yandell DW, et al. Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas. Cancer Res. 1993;53:846–50.

Sarbia M, Stahl M, Fink U, Willers R, Seeber S, Gabbert HE. Expression of apoptosis-regulating proteins and outcome of esophageal cancer patients treated by combined therapy modalities. Clin Cancer Res. 1998;4:2991–7.PubMed

Yang B, Rice TW, Adelstein DJ, Rybicki LA, Goldblum JR. Overexpression of p53 protein associates decreased response to chemoradiotherapy in patients with esophageal carcinoma. Mod Pathol. 1999;12:251–6.PubMed

Krasna MJ, Mao YS, Sonett JR, Tamura G, Jones R, Suntharalingam M, et al. P53 gene protein overexpression predicts results of trimodality therapy in esophageal cancer patients. Ann Thorac Surg. 1999;68:2021–4.PubMedCrossRef

10.

Samejima R, Kitajima Y, Yunotani S, Miyazaki K. Cyclin D1 is a possible predictor of sensitivity to chemoradiotherapy for esophageal squamous cell carcinoma. Anticancer Res. 1999;19:5515–21.PubMed

11.

Yamamoto M, Tsujinaka T, Shiozaki H, Doki Y, Tamura S, Inoue M, et al. Metallothionein expression correlates with the pathological response of patients with esophageal cancer undergoing preoperative chemoradiation therapy. Oncology. 1999;56:332–7.PubMedCrossRef

12.

Kitamura K, Saeki H, Kawaguchi H, Araki K, Ohno S, Kuwano H, et al. Immunohistochemical status of the p53 protein and Ki-67 antigen using biopsied specimens can predict a sensitivity to neoadjuvant therapy in patients with esophageal cancer. Hepatogastroenterology. 2000;47:419–23.PubMed

13.

Miyata H, Doki Y, Shiozaki H, Inoue M, Yano M, Fujiwara Y, et al. CDC25B and p53 are independently implicated in radiation sensitivity for human esophageal cancers. Clin Cancer Res. 2000;6:4859–65.PubMed

14.

Shimada H, Hoshino T, Okazumi S, Matsubara H, Funami Y, Nabeya Y, et al. Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma. Br J Cancer. 2002;86:552–7.PubMedCentralPubMedCrossRef

15.

Kishi K, Doki Y, Miyata H, Yano M, Yasuda T, Monden M. Prediction of the response to chemoradiation and prognosis in oesophageal squamous cancer. Br J Surg. 2002;89:597–603.PubMedCrossRef

16.

Takeuchi H, Ozawa S, Ando N, Kitagawa Y, Ueda M, Kitajima M. Cell-cycle regulators and the Ki-67 labeling index can predict the response to chemoradiotherapy and the survival of patients with locally advanced squamous cell carcinoma of the esophagus. Ann Surg Oncol. 2003;10:792–800.PubMedCrossRef

17.

Okumura H, Natsugoe S, Matsumoto M, Mataki Y, Takatori H, Ishigami S, et al. The predictive value of p53, p53R2, and p21 for the effect of chemoradiation therapy on oesophageal squamous cell carcinoma. Br J Cancer. 2005;92:284–9.PubMedCentralPubMed

18.

Sunada F, Itabashi M, Ohkura H, Okumura T. p53 negativity, CDC25B positivity, and metallothionein negativity are predictors of a response of esophageal squamous cell carcinoma to chemoradiotherapy. World J Gastroenterol. 2005;11:5696–700.PubMed

19.

Sarbia M, Ott N, Pühringer-Oppermann F, Brücher BL. The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of the oesophagus. Br J Cancer. 2007;97:1404–8.PubMedCentralPubMedCrossRef

20.

Makino T, Yamasaki M, Miyata H, Yoshioka S, Takiguchi S, Fujiwara Y, et al. p53 mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer. Ann Surg Oncol. 2010;17:804–11.PubMedCrossRef

21.

Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253:49–53.PubMedCrossRef

22.

Natsugoe S, Nakashima S, Matsumoto M, Xiangming C, Okumura H, Kijima F, et al. Expression of p21WAF1/Cip1 in the p53-dependent pathway is related to prognosis in patients with advanced esophageal carcinoma. Clin Cancer Res. 1999;5:2445–9.PubMed

23.

Shinozaki H, Ozawa S, Ando N, Tsuruta H, Terada M, Ueda M, et al. Cyclin D1 amplification as a new predictive classification for squamous cell carcinoma of the esophagus, adding gene information. Clin Cancer Res. 1996;2:1155–61.PubMed

24.

Brücher BL, Keller G, Werner M, Müller U, Lassmann S, Cabras AD, et al. Using Q-RT-PCR to measure cyclin D1, TS, TP, DPD, and Her-2/neu as predictors for response, survival, and recurrence in patients with esophageal squamous cell carcinoma following radiochemotherapy. Int J Colorectal Dis. 2009;24:69–77.PubMedCrossRef

25.

Nishijima H, Nishitani H, Seki T, Nishimoto T. A dual-specificity phosphatase cdc25B is an unstable protein and triggers p34cdc2/cyclinB activation in hamster BHK21 cells arrested with hydroxyurea. J Cell Biol. 1997;138:1105–16.PubMedCrossRef

26.

Lammer CL, Wagerer S, Saffrich R, Mertens D, Ansorge W, Hoffmann I. The cdc25B phosphatase is essential for the G2/M transition in human cells. J Cell Sci. 1998;111:2445–53.PubMed

27.

Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature. 1999;401:616–20.PubMedCrossRef

28.

Okumura H, Natsugoe S, Matsumoto M, Yokomakura N, Uchikado Y, Takatori H, et al. Predictive value of p53 and 14-3-3sigma for the effect of chemoradiation therapy on esophageal squamous cell carcinoma. J Surg Oncol. 2005;91:84–9.PubMedCrossRef

29.

Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, et al. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature. 2000;404:42–9.PubMedCrossRef

30.

Yamaguchi T, Matsuda K, Sagiya Y, Iwadate M, Fujimoto MA, Nakamura Y, et al. p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint. Cancer Res. 2001;61:8256–62.PubMed

31.

Kwon HC, Roh M, Oh SY, Kim SH, Kim MC, Kim JS, et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol. 2007;18:504–9.PubMedCrossRef

32.

Joshi MB, Shirota Y, Danenberg KD, Conlon DH, Salonga DS, Herndon JE 2nd, et al. High gene expression of TS1, GSTP1, and ERCC1are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res. 2005;11:2215–21.PubMedCrossRef

33.

Kim MK, Cho KJ, Kwon GY, Park SI, Kim YH, Kim JH, et al. ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. Eur J Cancer. 2008;44:54–60.PubMedCrossRef

34.

Hamer DH. Metallothionein. Annu Rev Biochem. 1986;55:913–51.PubMedCrossRef

35.

Kondo Y, Rusnak JM, Hoyt DG, Settineri CE, Pitt BR, Lazo JS. Enhanced apoptosis in metallothionein null cells. Mol Pharmacol. 1997;52:195–201.PubMed

36.

Backer MV, Hamby CV, Backer JM. Inhibition of vascular endothelial growth factor receptor signaling in angiogeneic tumor vasculature. Adv Genet. 2009;67:1–27.PubMedCrossRef

37.

Kulke MH, Odze RD, Mueller JD, Wang H, Redston M, Bertagnolli MM. Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer. J Thorac Cardiovasc Surg. 2004;127:1579–86.PubMedCrossRef

38.

Furukawa T, Yoshimura A, Sumizawa T, Haraguchi M, Akiyama S, Fukui K, et al. Angiogenic factor. Nature. 1992;356:668.PubMedCrossRef

39.

Subbaramaiah K, Telang N, Ramonetti JT, Araki R, DeVito B, Weksler BB, et al. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res. 1996;56:4424–9.PubMed

40.

Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest. 2000;105:1589–94.PubMedCentralPubMedCrossRef

41.

Takatori H, Natsugoe S, Okumura H, Matsumoto M, Ishigami S, Owaki T, et al. Predictive value of COX-2 for the effect of chemoradiotherapy on esophageal squamous cell carcinoma. Oncol Rep. 2005;13:697–701.PubMed

42.

Youssef EM, Matsuda T, Takada N, Osugi H, Higashino M, Kinoshita H, et al. Prognostic significance of the MIB-1 proliferative index for patients with squamous cell carcinoma of the esophagus. Cancer. 1995;76:358–66.PubMedCrossRef

43.

Lam KY, Law SYK, So MKP, Fok M, Ma LT, Wong J. Prognostic implication of proliferative markers MIB-1 and PC10 in esophageal squamous cell carcinoma. Cancer. 1996;77:7–13.PubMedCrossRef

44.

Ingham PW, McMahon AP. Hedgehog signaling in animal development: paradigms and principles. Genes Dev. 2001;15:3059–87.PubMedCrossRef

45.

van den Brink GR, Hardwick JC, Tytgat GN, Brink MA, Ten Kate FJ, Van Deventer SJ, et al. Sonic hedgehog regulates gastric gland morphogenesis in man and mouse. Gastroenterology. 2001;121:317–28.PubMedCrossRef

46.

Yoshikawa R, Nakano Y, Tao L, Koishi K, Matsumoto T, Sasako M, et al. Hedgehog signal activation in oesophageal cancer patients undergoing neoadjuvant chemoradiotherapy. Br J Cancer. 2008;98:1670–4.PubMedCentralPubMedCrossRef

47.

Zhu W, You Z, Li T, Yu C, Tao G, Hu M, et al. Correlation of hedgehog signal activation with chemoradiotherapy sensitivity and survival in esophageal squamous cell carcinomas. Jpn J Clin Oncol. 2011;41:386–93.PubMedCrossRef

48.

Kim MK, Cho KJ, Kwon GY, Park SI, Kim YH, Kim JH, et al. Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy. Clin Cancer Res. 2008;14:4225–31.PubMedCrossRef

49.

Okumura H, Natsugoe S, Yokomakura N, Kita Y, Matsumoto M, Uchikado Y, et al. Expression of p53R2 is related to prognosis in patients with esophageal squamous cell carcinoma. Clin Cancer Res. 2006;12:3740–5.PubMedCrossRef

50.

Hironaka S, Hasebe T, Kamijo T, Ohtsu A, Boku N, Yoshida S, et al. Biopsy specimen microvessel density is a useful prognostic marker in patients with T(2–4)M(0) esophageal cancer treated with chemoradiotherapy. Clin Cancer Res. 2002;8:124–30.PubMed

Title: Biomarkers for predicting the response of esophageal squamous cell carcinoma to neoadjuvant chemoradiation therapy
Authors: Hiroshi Okumura
Yasuto Uchikado
Tetsuro Setoyama
Masataka Matsumoto
Tetsuhiro Owaki
Sumiya Ishigami
Shoji Natsugoe
Publication date: 01-03-2014
Publisher: Springer Japan
Published in: Surgery Today / Issue 3/2014
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI: https://doi.org/10.1007/s00595-013-0580-y

At a glance: The STEP trials

Springer Medicine

Biomarkers for predicting the response of esophageal squamous cell carcinoma to neoadjuvant chemoradiation therapy

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2014

Single-incision laparoscopic herniorrhaphy for inguinal hernia repair

Use of a vessel sealing system versus conventional electrocautery for lung parenchymal resection: a comparison of the clinicopathological outcomes in porcine lungs

Single-port laparoscopic management of adhesive small bowel obstruction

Minimally invasive aortic valve replacement with orthotopic liver transplantation: report of a case

MRI findings of lumbosacral metastasis from occult follicular thyroid cancer: report of a case

Acute exacerbation of interstitial lung disease with lung cancer after surgery: evaluation with 2-[18]-fluoro-2-deoxy-d-glucose positron emission tomography